Should You Buy Cboe Global Markets Inc (CBOE) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
265.520
1 Day change
0.35%
52 Week Range
279.330
Analysis Updated At
2026/01/28
Buy now for a beginner, long-term investor. CBOE is in a broader uptrend (bullish moving-average stack) and just pulled back close to support (~264). Fundamentals (2025/Q3 double-digit revenue growth and strong EPS growth) and generally constructive Wall Street targets (mostly $265–$310) support a long-term position, and options positioning leans bullish (put/call ratios < 1).
Technical Analysis
Trend/price context: CBOE is in a longer-term uptrend with bullish moving averages (SMA_5 > SMA_20 > SMA_200), but short-term momentum has softened.
Momentum:
- MACD histogram: -0.0726 and negatively expanding -> short-term bearish momentum/pullback.
- RSI(6): ~41.95 -> neutral-to-slightly weak (not oversold).
Key levels:
- Current price: 266.17
- Pivot: 270.922 (price below pivot = near-term caution)
- Support: S1 264.207, then S2 260.058
- Resistance: R1 277.638, then R2 281.787
Interpretation: This looks like a dip within an uptrend. With price sitting just above S1 support and the longer-term trend still bullish, it’s a reasonable long-term entry even though near-term momentum is currently negative.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment from options:
- Open Interest Put/Call = 0.71 (more calls than puts outstanding) -> bullish tilt.
- Volume Put/Call = 0.88 -> slightly more call volume than put volume (mild bullish).
- IV (30d) ~22.11 vs Hist Vol ~21.51; IV percentile ~45 -> options pricing is fairly normal (not extreme fear/greed).
- Today’s option volume is below the 30-day average (~44.6% of avg) -> sentiment is positive but not “crowded” today.
Technical Summary
Sell
3
Buy
7
Positive Catalysts
- Corporate/operational execution: New senior leadership appointments (COO and EVP) support the company’s global strategy and operating cadence.
- Earnings catalyst: Next earnings (QDEC 2025) scheduled 2026-02-06 pre-market; recent commentary from analysts points to healthy volumes and improved volatility conditions.
- Business backdrop: Exchange operators often benefit from higher market activity/volatility; recent analyst notes reference rising volumes across equities/options/futures.
- Shareholder return: Dividend yield noted around ~1.1% (modest but supportive for long-term holders).
Neutral/Negative Catalysts
- Near-term technical drag: MACD is negative and worsening, suggesting the stock could chop or drift lower before resuming the broader uptrend.
- Event risk around earnings (2026-02-06): A miss vs expectations could pressure the stock short term.
- Mixed Street view remains: Morgan Stanley is Underweight with a lower target (though others are Neutral/Overweight), which can cap near-term multiple expansion if results don’t exceed expectations.
- No notable supportive flow signals from institutions/insiders in the provided trends (both described as Neutral).
Financial Performance
Latest quarter provided: 2025/Q3.
- Revenue: $668.4M, +13.06% YoY (solid top-line growth).
- Net income: $299.3M, +37.67% YoY (strong profitability expansion).
- EPS: $2.85, +37.68% YoY (strong per-share growth).
- Gross margin: 85.97% (+1.61% YoY), indicating excellent and improving margin profile.
Bottom line: Growth is accelerating at the earnings level faster than revenue, which is typically a favorable setup for long-term compounding if activity levels remain healthy.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Price targets have generally moved up into late 2025 and early 2026, with a notable upgrade from Barclays to Overweight (and targets in the ~$280–$310 range from several firms).
Latest notable changes:
- Barclays (2026-01-08): PT trimmed to $295 from $302, kept Overweight (still positive).
- UBS (2026-01-07): PT raised to $280 from $265, kept Neutral.
- Morgan Stanley (2025-12-22): PT raised to $240 from $221, kept Underweight.
- BofA (2025-12-10): PT raised to $310 from $271, kept Neutral.
Wall Street pros vs cons view:
- Pros: Strong/defensible index options franchise, improving strategy under new CEO, healthy volume environment, and strong recent quarter growth.
- Cons: Valuation sensitivity and some skepticism (Underweight at Morgan Stanley) suggesting upside may rely on continued volume/volatility strength and clean execution.
Politicians/congress trading: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast CBOE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBOE is 274.55 USD with a low forecast of 230 USD and a high forecast of 310 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast CBOE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBOE is 274.55 USD with a low forecast of 230 USD and a high forecast of 310 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
8 Hold
2 Sell
Hold
Current: 264.600
Low
230
Averages
274.55
High
310
Current: 264.600
Low
230
Averages
274.55
High
310
Barclays
Benjamin Budish
Overweight
downgrade
$302 -> $295
AI Analysis
2026-01-08
Reason
Barclays
Benjamin Budish
Price Target
$302 -> $295
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Barclays analyst Benjamin Budish lowered the firm's price target on Cboe Global Markets to $295 from $302 and keeps an Overweight rating on the shares. The firm updated targets in the brokers, asset managers and exchanges group ahead of the Q4 reports. Total volumes across equities, options, and futures "rose nicely" quarter-over-quarter and volatility picked up sequentially, the analyst tells investors in a research note.
UBS
Neutral
maintain
$265 -> $280
2026-01-07
Reason
UBS
Price Target
$265 -> $280
2026-01-07
maintain
Neutral
Reason
UBS raised the firm's price target on Cboe Global Markets to $280 from $265 and keeps a Neutral rating on the shares. Strength likely carries into 2026 for now, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CBOE
